Do you want to read an article? Please log in or register.
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study
Macular Diseases
Related content
Macular DiseasesRetinal Diseases
One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration
Br J Ophthalmol.
Braimah IZ, Agarwal K, Mansour A, Chhablani J; Ziv-aflibercept Study Group
doi: 10.1136/bjophthalmol-
COMMENTED
Macular Diseases
Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
doi: 10.1016/j.ophtha.2019.11.004.
Macular Diseases
Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19
Ophthalmol Retina.
Keenan TD, Vitale S, Agrón E, Domalpally A, Antoszyk AN, Elman MJ, Clemons TE, Chew EY, Age-Related Eye Disease Study 2 Research Group.
doi: 10.1016/j.oret.2019.06.001.
Macular DiseasesRetinal Diseases
Peripheral Retinal Changes Associated with Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 12 by the Age-Related Eye Disease Study 2 Optos PEripheral RetinA (OPERA) Study Research Group
Ophthalmology.
Writing Committee for the OPTOS PEripheral RetinA (OPERA) study (Ancillary Study of Age-Related Eye Disease Study 2), Domalpally A, Clemons TE, Danis RP, Sadda SR, Cukras CA, Toth CA, Friberg TR, Chew EY
doi: 10.1016/j.ophtha.2016.12.004.
Macular Diseases
Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study
Acta Ophthalmol
Saenz-de-Viteri M, Recalde S, Fernandez-Robredo P, López Gálvez MI, Arias Barquet L, Figueroa MS, García-Arumí J, García-Layana A, In-Eye Study Group.
doi: 10.1111/aos.14786
Macular Diseases
Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study)
Ophthalmology.
Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Pecheur FL, Munk MR, McAllister IL
doi: 10.1016/j.ophtha.2019.08.023.
Macular DiseasesRetinal Diseases
Six-year outcomes in neovascular age-related macular degeneration with ranibizumab
Int J Ophthalmol.
Jacob J, Brié H, Leys A, Levecq L, Mergaerts F, Denhaerynck K, Vancayzeele S, Van Craeyveld E, Abraham I, MacDonald K
doi: 10.18240/ijo.2017.01.14.
Macular Diseases
Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry
Ophthalmology.
Bhandari S, Nguyen V, Arnold J, Young S, Banerjee G, Gillies M, Barthelmes D
doi: 10.1016/j.ophtha.2019.10.006.
COMMENTED
Macular Diseases
Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
JAMA Ophthalmol.
Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL
doi: 10.1001/jamaophthalmol.